Carlo V. Catapano

Seedless 3′ pairing enables miR-17 family miRNAs to seize let-7 target sites

Artur Łaski, Anneke Brümmer, Matije Lucic, Elisa Federici et autres

ch, de, us (code pays fourni par la source)

Loss of ESE3/EHF is sufficient to promote cell plasticity, transformation and androgen-independent status in the early stage of prostate carcinogenesis

Domenico Albino, Giada Sandrini, Carola Musumeci, Elisa Storelli et autres

ch, pt, it (code pays fourni par la source)

Integrated control of cancer stemness by σ1 receptor in advanced prostate cancer

Gianluca Civenni, Giada Sandrini, Jessica Merulla, Carola Musumeci et autres

ch, it, de (code pays fourni par la source)

ZEB1 stratifies the response to Sorafenib and Mdivi-1 combination therapy in hepatocellular carcinoma

Henry Freudenstein, Marco Strecker, Severin Gylstorff, Wenjie Shi et autres

de, ch (code pays fourni par la source)

Abstract 311: Long-term tumor growth inhibition and extended survival with TD001, a novel optimized PSMA-targeting ADC, in PSMA-expressing CRPC CDX castrated mouse models

Daniela Impellizzieri, Elisa Storelli, André Balla, Simone Mosole et autres

ch, it (code pays fourni par la source)

Abstract 318: Optimal free exatecan payload tumor/plasma ratio of TD001, a new ADC against PSMA, in CRPC CDX mouse models

Lavinia Morosi, Daniela Impellizzieri, Roberta Frapolli, Elisa Storelli et autres

it (code pays fourni par la source)

Abstract 314: Improved tumor penetration and cytotoxic payload release with TD001, a novel PSMA-targeting ADC with optimized linker-payload composition, in PSMA-expressing CRPC CDX castrated mouse models

Daniela Impellizzieri, Elisa Storelli, André Balla, Simone Mosole et autres

ch, it (code pays fourni par la source)

Abstract 315: Dose-response and tumor size at time of treatment with TD001, a novel ADC against PSMA, drive potent tumor growth inhibition in a CRPC CDX castrated mouse model

Roberta Frapolli, Ezia Bello, Marina Meroni, Daniela Impellizzieri et autres

it, ch (code pays fourni par la source)

1843P Safety of immunotherapy in cancer patients with comorbidities: Results of the phase IV Italian immuno-special trial

Davide Smussi, M. Carpani, Simone Vetrugno, Carlo V. Catapano et autres

it (code pays fourni par la source)

Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer

Alessia Cacciatore, Dheeraj Shinde, Carola Musumeci, Giada Sandrini et autres

ch, it (code pays fourni par la source)

Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer

Luigi Ippolito, Assia Duatti, Marta Iozzo, Giuseppina Comito et autres

it, ch (code pays fourni par la source)

Methionine Adenosyltransferase 2a (MAT2A) is a driver and an actionable therapeutic target in androgen-indifferent prostate tumors

Alessia Cacciatore, Carola Musumeci, Domenico Albino, Giada Sandrini et autres